Authors and Disclosures
Andrew Charles MD, Sinifunanya E. Nwaobi MD, PhD and Peter Goadsby MD, PhD
UCLA Goldberg Migraine Program, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
Correspondence
Andrew Charles, UCLA Goldberg Migraine Program, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Email: acharles@ucla.edu
Conflict of Interest
Dr. Charles reports personal fees from Amgen, Biohaven, Eli Lilly, Lundbeck, Satsuma, UCB Pharma, and My Everyday Health outside the submitted work. Dr. Nwaobi reports no conflict. Dr. Goadsby reports personal fees from Aeon Biopharma, Alder Biopharmaceuticals, Allergan, Biohaven Pharmaceuticals Inc., Clexio, eNeura Inc., Epalex, GlaxoSmithKline, Impel Neuropharma, Lundbeck, Novartis, Pfizer, Praxis, Santara Therapeutics, Sanofi, Satsuma, Dr Reddy's; grants and personal fees from Amgen, Eli Lilly and Company, Electrocore LLC; grants from Celgene; personal fees from Teva Pharmaceuticals, other from Trigemina Inc., outside the submitted work. In addition, Dr. Goadsby has a patent magnetic stimulation for headache licensed to eNeura without fee and fees for advice through Gerson Lehrman Group and Guidepoint, and fees for educational materials from Medery, Medlink, PrimeEd, UptoDate, WebMD, and fees for publishing from Oxford University Press, Massachusetts Medical Society, and Wolters Kluwer, and for medicolegal advice in headache.
Author Contributions
Andrew Charles, Sinifunanya E. Nwaobi, and Peter Goadsby all contributed to the review of the literature and the writing of this article.
